Announcements Trials

Browse Landscape

Phase

Phase 2 5 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 2 Urinary Bladder Neoplasms 1 Precancerous Conditions 1 Polyps 1 Neoplastic Syndromes, Hereditary 1 Mouth Neoplasms 1 Keratosis, Actinic 1 Intestinal Neoplasms 1 Intestinal Diseases 1 Genetic Diseases, Inborn 1 Gastrointestinal Neoplasms 1 Gastrointestinal Diseases 1 Duodenal Neoplasms 1 Digestive System Neoplasms 1 Digestive System Diseases 1 Adenomatous Polyps 1 Adenomatous Polyposis Coli 1 Adenoma 1

Interventions

Magnetic Resonance Spectroscopy 2 Immunoglobulin G 2 Disulfides 2 Cetuximab 2 (225)Ac-DOTA-c(RGDyK) 2 pembrolizumab 1 durvalumab 1 atezolizumab 1 acetyl-glycyl-asparagyl-glutaminyl-glutamyl-glutaminyl-valyl-seryl-prolyl-leucyl-threonyl-leucyl-leucyl-lysyl-lysyl-tryptophyl-cysteinyl-Alexa Fluoro 680 C2C2-maleimide conjugate 1 X-Rays 1 Thalidomide 1 Standard of Care 1 Specimen Handling 1 Sentinel Lymph Node Biopsy 1 Radiotherapy, Intensity-Modulated 1 Radiotherapy 1 Radiation 1 Platinum 1 Pilocarpine 1 Photons 1 Neck Dissection 1 Fluorouracil 1 Fluorodeoxyglucose F18 1 Drug Therapy 1 Docetaxel 1 Dexamethasone 1 Cyclophosphamide 1 Cisplatin 1 Chemotherapy, Adjuvant 1 Celecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Mouth Neoplasms × Celecoxib × Clear all

NCT00934739 2015-02-25

A Study of High-Risk Oral Cavity Cancer

National Health Research Institutes, Taiwan

Phase 2/3 Terminated

Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡